Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, including biological therapies, vaccines and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services for the prevention, treatment and control of disease in all major livestock and companion animal species.

  • Revenue in USD (TTM)57.87bn
  • Net income in USD13.03bn
  • Incorporated1970
  • Employees69.00k
  • Location
    Merck & Co Inc2000 Galloping Hill RoadKENILWORTH 07033United StatesUSA
  • Phone+1 (908) 740-4000
  • Fax+1 (908) 423-1987
  • Websitehttps://www.merck.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
MRK:NYQ since
Prometheus Biosciences IncAnnounced16 Apr 202316 Apr 2023Announced-3.56%10.93bn
Seagen IncPrior rumour discounted17 Jun 202217 Jun 2022Prior rumour discounted31.00%--
Data delayed at least 15 minutes, as of Jun 09 2023 20:23 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.